MedTrace Logo

Safety and Tolerability Study of INNO-406 to Treat Chronic Myeloid Leukemia or Acute Lymphocytic Leukemia

NCT00352677 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2009-06-01

No results posted yet for this study

Summary

The purpose of this study is to determine the safety and effectiveness of INNO-406 in adult patients with imatinib-resistant or intolerant Philadelphia chromosome-positive (Ph+) leukemias.

Conditions

  • Chronic Myeloid Leukemia
  • Acute Lymphocytic Leukemia

Interventions

DRUG

INNO-406

Oral, twice daily self-administration of 10 mg and/or 50 mg tablets

Sponsors & Collaborators

  • CytRx

    lead INDUSTRY

Principal Investigators

  • Hagop Kantarjian, M.D. · University of Texas, MD Anderson Cancer Center, Houston, TX 713-792-7026 [email protected]

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-07-31
Primary Completion
2008-05-31
Completion
2008-05-31

Countries

  • United States
  • Germany
  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00352677 on ClinicalTrials.gov